Selective class IIa HDAC inhibitors: myth or reality

Area of Science:

• Biomedical science
• Molecular biology
• Epigenetics
• Pharmacology

Background:

• Epigenetic-based therapies, particularly histone deacetylase inhibitors (HDACis), show promise for treating various disorders, including cancer.
• HDACs are key targets for resetting aberrant genetic programs and restoring normal cellular functions, such as drug responsiveness.
• Current HDAC inhibitors face challenges with selectivity and general toxicity, necessitating the development of subtype-specific agents.

Purpose of the Study:

• To discuss a set of molecules designed to interfere with the activity of a specific subclass of HDACs: the class IIa.
• To highlight the potential of subtype-specific inhibitors for increasing selectivity and managing toxicity in epigenetic therapies.

Main Methods:

• Review and discussion of a specific set of molecules targeting class IIa histone deacetylases.
• Analysis of the potential of these molecules as subtype-specific HDAC inhibitors.

Main Results:

• Identification of molecules capable of interfering with class IIa HDAC activity.
• Potential for enhanced selectivity and reduced toxicity compared to broad-spectrum HDAC inhibitors.

Conclusions:

• Class IIa HDAC inhibitors represent a promising new frontier in epigenetic therapy.
• Targeted inhibition of specific HDAC subtypes offers a strategy to improve therapeutic efficacy and safety in diseases like cancer.